Durable complete responses from therapy with combined epratuzumab and rituximab : Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma
✍ Scribed by John P. Leonard; Stephen J. Schuster; Christos Emmanouilides; Felix Couture; Nick Teoh; William A. Wegener; Morton Coleman; David M. Goldenberg
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 134 KB
- Volume
- 113
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND.
In this international, multicenter trial, the authors evaluated rituximab (anti‐CD20) plus epratuzumab (anti‐CD22) in patients with postchemotherapy relapsed/refractory, indolent non‐Hodgkin lymphoma (NHL), including long‐term efficacy.
METHODS.
Forty‐nine patients with follicular NHL (FL) (N = 41) or small lymphocytic lymphoma (SLL) (N = 7) received intravenous epratuzumab 360 mg/m^2^ and then intravenous rituximab 375 mg/m^2^ weekly ×4. The regimen was tolerated well.
RESULTS.
Twenty‐two of 41 patients with FL (54%) had an objective response (OR), including 10 (24%) complete responses (CR) (CR/unconfirmed CR [CRu]), whereas 4 of 7 patients with SLL (57%) had ORs, including 3 (43%) with CR/CRu. Rituximab‐naive patients (N = 34) had an OR rate of 50% (26% CR/CRu rate), whereas patients who previously responded to rituximab (N = 14) had an OR rate of 64% (29% CR/CRu rate). An OR rate of 85% was observed in patients with FL who had Follicular Lymphoma International Prognostic Index (FLIPI) risk scores of 0 or 1 (N = 13), whereas 28 patients with intermediate or high‐risk FLIPI scores (≥2) had an OR rate of 39% (18% CR/CRu rate). In patients with FL, the median response duration was 13.4 months, and that duration increased to 29.1 months for 10 patients who had a CR/CRu, including 4 patients who had durable responses with remissions that continued for >4 years. In patients with SLL, the median response duration was 20 months, including 1 patient who had a response that continued for >3 years.
CONCLUSIONS.
The combination of epratuzumab and rituximab induced durable responses in patients with recurrent, indolent NHL. Cancer 2008. © 2008 American Cancer Society.